RxDoctor Payments DataLook up a doctor →

Benedetto Palombo

Psychiatric/Mental Health · Charlotte, NCNPI 1255691150

Payments from drug & device makers

$670,579in general payments, 2019–2025

Across 866 payments — averaging $774.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$518K
  • Teva Pharmaceuticals USA, Inc.$139K
  • Otsuka America Pharmaceutical, Inc.$13K
  • Johnson & Johnson$125
  • Masimo Corporation$13

What the payments were for

  • Consulting fees$41,5626%
  • Speaking & faculty fees$535,53580%
  • Travel & lodging$77,98412%
  • Food & beverage$15,4992%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$670,579 in reported general payments places this provider in the 95th percentile of 947 psychiatric/mental health providers in North Carolina.

See all psychiatric/mental health providers in North Carolina

Medicare billing

Part B allowed, 2024
$155,728
Medicare patients
455
Services billed
1,696

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate201$1,143,269
AustedoDeutetrabenazine85$530,820
Austedo XrDeutetrabenazine50$305,169
RexultiBrexpiprazole106$91,972
Invega SustennaPaliperidone Palmitate19$60,703
BiktarvyBictegrav/Emtricit/Tenofov Ala11$46,712
Divalproex Sodium637$30,346
AuvelityDextromethorphan Hbr/Bupropion45$27,148
Mirtazapine402$11,296
Olanzapine359$10,376
Trazodone Hcl549$9,757
Sertraline Hcl460$7,771
Quetiapine Fumarate254$7,501
Escitalopram Oxalate408$7,016
Risperidone177$4,672

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$517,749$1,143,269201 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$139,447$835,989135 claims
Otsuka America Pharmaceutical, Inc.Rexulti$13,246$91,972106 claims
Johnson & JohnsonInvega Sustenna$125$60,70319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 947 psychiatric/mental health providers in North Carolina.

Other psychiatric/mental health in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →